… that determine the feasibility of administering high-dose TKIs. In a … is the optimal biologic
dose reported for gefitinib [44,45,46,47]. To the best of our knowledge, this is the first study to …

… Reckamp KL, Krysan K, Morrow JD, et al: A phase I trial to determine the optimal biological
dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin …

… Recently, molecularly targeted agents, such as erlotinib and … determine if side effects
increase when a drug is combined … this advanced method, the PFS or OS value of the celecoxib …

… The anti-cancer role of celecoxib is through various intrinsic … A phase I clinical trial showed
that a combination of erlotinib … dose-limiting toxicity (DLT) rate and maximum tolerated dose (…

… innovative therapies for non-small cell lung cancer (NSCLC). … therapy with celecoxib at 600
mg twice daily and erlotinib … the optimal biological dose of a COX-2 inhibitor, celecoxib, to …

… Cancer Cachexia evaluating Resistance Training Study A randomised feasibility study of
EPA and Cox-2 inhibitor (Celecoxib) versus EPA, Cox-2 inhibitor (Celecoxib), Progressive …

… , gefitinib, and erlotinib as active agents in lung cancer. For the … treatments for stage IV
non-small cell lung cancer (NSCLC). … has focused on the selective COX-2 inhibitors celecoxib and …

… in an oncology trial for non‑small cell lung cancer patients … activity (mAb cetuximab and RTKIs
gefitinib and erlotinib) (16,17). … against COX2 [such as celecoxib (Celebrex) and etoricoxib (…

… in the treatment of advanced non–small-cell lung cancer. Despite … erlotinib have shown
clinical activity in pretreated, advanced … This study assessed the role of cetuximab in combination …

… are administered at doses close to the maximum tolerated dose (MTD), … phase I trial, the
combination of celecoxib with erlotinib was assessed in patients with non-small cell lung cancer…